Reevaluating the lower limit of renal autoregulation: does one size fit all?

Renal autoregulation plays a crucial role in maintaining stable renal blood flow despite fluctuations in systemic arterial pressure. Existing paradigms, largely based on animal studies, suggest an autoregulation lower limit of 80 mmHg. However, the direct applicability of these findings to human physiology and clinical practice remains uncertain. Accordingly performed a comprehensive literature review to reevaluate the evidence about the lower limit of renal autoregulation. Animal and human studies were identified to assess the variability of the lower limit of renal autoregulation across different species, the influence of chronic conditions and acute interventions on this threshold, and the impact of blood pressure management strategies in critical care and anesthesia settings. We identified a broad range of lower limits of renal autoregulation, which were significantly influenced by experimental conditions and species differences. Human studies suggest that the autoregulation threshold might be lower than the traditionally mentioned 80 mmHg, with evidence indicating that renal function can be preserved at <80 mmHg mean arterial pressure levels. Moreover, clinical trials did not document a deterioration in renal function with blood pressure targets <80 mmHg. In individuals with diabetes, hypertension, or renal insufficiency the lower limit of autoregulation was increased. In humans there is insufficient evidence to state that 80 mmHg is the lower limit of renal autoregulation. This 80 mmHg threshold was also inconsistently identified in dog and mouse studies. Some human disease, however, may alter the limits of such autoregulation. Further research is warranted to define the value of the autoregulation threshold in human disease.

Renal autoregulation; Tubuloglomerular feedback; Kidney; Blood pressure

[1] Carlström M, Wilcox CS, Arendshorst WJ. Renal autoregulation in health and disease. Physiological Reviews. 2015; 95: 405–511.

[2] Sladen RN, Landry D. Renal blood flow regulation, autoregulation, and vasomotor nephropathy. Anesthesiology Clinics of North America. 2000; 18: 791–807.

[3] Loutzenhiser R, Griffin K, Williamson G, Bidani A. Renal autoregulation: new perspectives regarding the protective and regulatory roles of the underlying mechanisms. The American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. 2006; 290: R1153–R1167.

[4] Post EH, Vincent JL. Renal autoregulation and blood pressure management in circulatory shock. Critical Care. 2018; 22: 81.

[5] Harman PK, Kron IL, McLachlan HD, Freedlender AE, Nolan SP. Elevated intra-abdominal pressure and renal function. Annals of Surgery. 1982; 196: 594–597.

[6] Chen X, Wang X, Honore PM, Spapen HD, Liu D. Renal failure in critically ill patients, beware of applying (central venous) pressure on the kidney. Annals of Intensive Care. 2018; 8: 91.

[7] Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Critical Care Medicine. 2021; 49: e1063–e1143.

[8] Bass GA, Kaplan LJ, Ryan ÉJ, Cao Y, Lane-Fall M, Duffy CC, et al. The snapshot audit methodology: design, implementation and analysis of prospective observational cohort studies in surgery. European Journal of Trauma and Emergency Surgery. 2023; 49: 5–15.

[9] Alhujaili A, Nocella G, Macready A. Insects as food: consumers’ acceptance and marketing. Foods. 2023; 12: 886.

[10] Zaccagnini M, Li J. How to conduct a systematic review and meta-analysis: a guide for clinicians. Respiratory Care. 2023; 68: 1295–1308.

[11] Selkurt EE. The relation of renal blood flow to effective arterial pressure in the intact kidney of the dog. American Physiological Society Journal. 1946; 147: 537–549.

[12] Cupples WA, Braam B. Assessment of renal autoregulation. American Journal of Physiology-Renal Physiology. 2007; 292: F1105–F1123.

[13] Arendshorst WJ, Finn WF, Gottschalk CW. Autoregulation of blood flow in the rat kidney. American Physiological Society Journal. 1975; 228: 127–133.

[14] Persson PB, Ehmke H, Nafz B, Kirchheim HR. Sympathetic modulation of renal autoregulation by carotid occlusion in conscious dogs. American Physiological Society Journal. 1990; 258: F364–F370.

[15] McNay JL, Kishimoto T. Association between autoregulation and pressure dependency of renal vascular responsiveness in dogs. Circulation Research. 1969; 24: 599–605.

[16] Turkstra E, Braam B, Koomans HA. Impaired renal blood flow autoregulation in two-kidney, one-clip hypertensive rats is caused by enhanced activity of nitric oxide. Journal of the American Society of Nephrology. 2000; 11: 847–855.

[17] Pires SL, Julien C, Chapuis B, Sassard J, Barrès C. Spontaneous renal blood flow autoregulation curves in conscious sinoaortic baroreceptor-denervated rats. American Journal of Physiology-Renal Physiology. 2002; 282: F51–F58.

[18] Ogawa N. Effect of nicardipine on the relationship of renal blood flow and of renal vascular resistance to perfusion pressure in dog kidney. Journal of Pharmacy and Pharmacology. 1990; 42: 138–140.

[19] Nizet A. The isolated perfused kidney: possibilities, limitations and results. Kidney International. 1975; 7: 1–11.

[20] Sarubbi D, Quilley J. Evidence against a role of arachidonic acid metabolites in autoregulatory responses of the isolated perfused kidney of the rat. European Journal of Pharmacology. 1991; 197: 27–31.

[21] Scholz H, Kurtz A. Disparate effects of calcium channel blockers on pressure dependence of renin secretion and flow in the isolated perfused rat kidney. European Journal of Physiology. 1992; 421: 155–162.

[22] Cupples WA, Marsh DJ. Autoregulation of blood flow in renal medulla of the rat: no role for angiotensin II. Canadian Journal of Physiology and Pharmacology. 1988; 66: 833–836.

[23] Mattson DL, Lu S, Roman RJ, Cowley AW III. Relationship between renal perfusion pressure and blood flow in different regions of the kidney. American Physiological Society Journal. 1993; 264: R578–R583.

[24] Roman RJ, Cowley AW III, Garcia-Estañ J, Lombard JH. Pressure-diuresis in volume-expanded rats. Cortical and medullary hemodynamics. Hypertension. 1988; 12: 168–176.

[25] Stern MD, Bowen PD, Parma R, Osgood RW, Bowman RL, Stein JH. Measurement of renal cortical and medullary blood flow by laser-Doppler spectroscopy in the rat. American Physiological Society Journal. 1979; 236: F80–F87.

[26] Strick DM, Fiksen-Olsen MJ, Lockhart JC, Roman RJ, Romero JC. Direct measurement of renal medullary blood flow in the dog. American Physiological Society Journal. 1994; 267: R253–R259.

[27] Langenberg C, Bellomo R, May C, Wan L, Egi M, Morgera S. Renal blood flow in sepsis. Critical Care. 2005; 9: R363–R374.

[28] Christensen PK, Hansen HP, Parving HH. Impaired autoregulation of GFR in hypertensive non-insulin dependent diabetic patients. Kidney International. 1997; 52: 1369–1374.

[29] Christensen PK, Lund S, Parving HH. Autoregulated glomerular filtration rate during candesartan treatment in hypertensive type 2 diabetic patients. Kidney International. 2001; 60: 1435–1442.

[30] Christensen PK, Akram K, Kønig KB, Parving HH. Autoregulation of glomerular filtration rate in patients with type 2 diabetes during isradipine therapy. Diabetes Care. 2003; 26: 156–162.

[31] Christensen PK, Hommel EE, Clausen P, Feldt-Rasmussen B, Parving HH. Impaired autoregulation of the glomerular filtration rate in patients with nondiabetic nephropathies. Kidney International. 1999; 56: 1517–1523.

[32] Bourgoin A, Leone M, Delmas A, Garnier F, Albanèse J, Martin C. Increasing mean arterial pressure in patients with septic shock: effects on oxygen variables and renal function. Critical Care Medicine. 2005; 33: 780–786.

[33] LeDoux D, Astiz ME, Carpati CM, Rackow EC. Effects of perfusion pressure on tissue perfusion in septic shock. Critical Care Medicine. 2000; 28: 2729–2732.

[34] Asfar P, Meziani F, Hamel JF, Grelon F, Megarbane B, Anguel N, et al. High versus low blood-pressure target in patients with septic shock. The New England Journal of Medicine. 2014; 370: 1583–1593.

[35] Lamontagne F, Richards-Belle A, Thomas K, Harrison DA, Sadique MZ, Grieve RD, et al.; 65 trial investigators. Effect of reduced exposure to vasopressors on 90-day mortality in older critically ill patients with vasodilatory hypotension: a randomized clinical trial. JAMA Network. 2020; 323: 938–949.

[36] Kandler K, Nilsson JC, Oturai P, Jensen ME, Møller CH, Clemmesen JO, et al. Higher arterial pressure during cardiopulmonary bypass may not reduce the risk of acute kidney injury. Journal of Cardiothoracic Surgery. 2019; 14: 107.

[37] Azau A, Markowicz P, Corbeau JJ, Cottineau C, Moreau X, Baufreton C, et al. Increasing mean arterial pressure during cardiac surgery does not reduce the rate of postoperative acute kidney injury. Perfusion. 2014; 29: 496–504.

[38] Wanner PM, Wulff DU, Djurdjevic M, Korte W, Schnider TW, Filipovic M. Targeting higher intraoperative blood pressures does not reduce adverse cardiovascular events following noncardiac surgery. Journal of the American College of Cardiology. 2021; 78: 1753–1764.

[39] D’Amico F, Fominskiy EV, Turi S, Pruna A, Fresilli S, Triulzi M, et al. Intraoperative hypotension and postoperative outcomes: a meta-analysis of randomised trials. British Journal of Anaesthesia. 2023; 131: 823–831.

[40] D’Amico F, Pruna A, Putowski Z, Dormio S, Ajello S, Scandroglio AM, et al. Low versus high blood pressure targets in critically ill and surgical patients: a systematic review and meta-analysis of randomized controlled trials. Critical Care Medicine. 2024; 52: 1427–1438.

[41] Dang PT, Lopez BE, Togashi K. A decrease in effective renal perfusion pressure is associated with increased acute kidney injury in patients undergoing cardiac surgery. Cureus. 2023; 15: e45036.

[42] Kopitkó C, Medve L, Gondos T. The value of combined hemodynamic, respiratory and intra-abdominal pressure monitoring in predicting acute kidney injury after major intraabdominal surgeries. Renal Failure. 2019; 41: 150–158.

[43] Nawaz S, Chinnadurai R, Al-Chalabi S, Evans P, Kalra PA, Syed AA, et al. Obesity and chronic kidney disease: a current review. Obesity Science & Practice. 2022; 9: 61–74.

[44] Kotsis V, Martinez F, Trakatelli C, Redon J. Impact of obesity in kidney diseases. Nutrients. 2021; 13: 4482.

[45] Kanbay M, Copur S, Bakir CN, Covic A, Ortiz A, Tuttle KR. Glomerular hyperfiltration as a therapeutic target for CKD. Nephrology Dialysis Transplantation. 2024; 39: 1228–1238.

[46] Hall JE, Mouton AJ, da Silva AA, Omoto ACM, Wang Z, Li X, et al. Obesity, kidney dysfunction, and inflammation: interactions in hypertension. Cardiovascular Research. 2021; 117: 1859–1876.

[47] Arabi T, Shafqat A, Sabbah BN, Fawzy NA, Shah H, Abdulkader H, et al. Obesity-related kidney disease: beyond hypertension and insulin-resistance. Frontiers in Endocrinology. 2023; 13: 1095211.

[48] Ardiles LG. Obesity and renal disease: benefits of bariatric surgery. Frontiers in Medicine. 2023; 10: 1134644.

[49] De Bhailis ÁM, Kalra PA. Hypertension and the kidneys. British Journal of Hospital Medicine. 2022; 83: 1–11.

[50] Palmer BF. Impaired renal autoregulation: implications for the genesis of hypertension and hypertension-induced renal injury. The American Journal of the Medical Sciences. 2001; 321: 388–400.

[51] Thomas HY, Ford Versypt AN. Pathophysiology of mesangial expansion in diabetic nephropathy: mesangial structure, glomerular biomechanics, and biochemical signaling and regulation. Journal of Biological Engineering. 2022; 16: 19.

[52] Jha R, Lopez-Trevino S, Kankanamalage HR, Jha JC. Diabetes and renal complications: an overview on pathophysiology, biomarkers and therapeutic interventions. Biomedicines. 2024; 12: 1098.

[53] Russo G, Piscitelli P, Giandalia A, Viazzi F, Pontremoli R, Fioretto P, et al. Atherogenic dyslipidemia and diabetic nephropathy. Journal of Nephrology. 2020; 33: 1001–1008.

[54] Wühl E, Schaefer F. Renal hypertension: etiology and management. In Schaefer F, Greenbaum LA (eds.) Pediatric kidney disease (pp. 1337–1362). Springer: Cham. 2023.

[55] Habas E Sr, Al Adab A, Arryes M, Alfitori G, Farfar K, Habas AM, et al. Anemia and hypoxia impact on chronic kidney disease onset and progression: review and updates. Cureus. 2023; 15: e46737.

[56] Gallan AJ, Chang A. A new paradigm for renal thrombotic microangiopathy. Seminars in Diagnostic Pathology. 2020; 37: 121–126.

[57] Mansour AS. Autoregulation: mediators and renin–angiotensin system in diseases and treatments. Future Journal of Pharmaceutical Sciences. 2023; 9: 30.

[58] Khan S, Kingston J, Moinuddin Z. Renal physiology: blood flow, glomerular filtration, and plasma clearance. Anaesthesia & Intensive Care Medicine. 2024; 25: 344–347.

[59] Gérard AO, Laurain A, Favre G, Drici MD, Esnault VLM. Activation of the tubulo-glomerular feedback by SGLT2 inhibitors in patients with type 2 diabetes and advanced chronic kidney disease: toward the end of a myth? Diabetes Care. 2022; 45: e148–e149.

[60] van Ochten M, Westerhof BE, Spaanderman MEA, Antonius TAJ, van Drongelen J. Modeling renal autoregulation in a hemodynamic, first-trimester gestational model. Physiological Reports. 2022; 10: e15484.

[61] Edwards A, Kurtcuoglu V. Renal blood flow and oxygenation. European Journal of Physiology. 2022; 474: 759–770.

[62] Zehra T, Cupples WA, Braam B. Tubuloglomerular feedback synchronization in nephrovascular networks. Journal of the American Society of Nephrology. 2021; 32: 1293–1304.

[63] Upadhyay A. SGLT2 inhibitors and kidney protection: mechanisms beyond tubuloglomerular feedback. Kidney360. 2024; 5: 771–782.

[64] Lee B, Holstein-Rathlou NH, Sosnovtseva O, Sørensen CM. Renoprotective effects of GLP-1 receptor agonists and SGLT-2 inhibitors-is hemodynamics the key point? American Journal of Physiology-Cell Physiology. 2023; 325: C243–C256.

[65] Richfield O, Cortez R, Navar LG. Modeling the interaction between tubuloglomerular feedback and myogenic mechanisms in the control of glomerular mechanics. Frontiers in Physiology. 2024; 15: 1410764.

[66] More HL, Braam B, Cupples WA. Reduced tubuloglomerular feedback activity and absence of its synchronization in a connexin40 knockout rat. Frontiers in Physiology. 2023; 3: 1208303.

[67] Just A. Mechanisms of renal blood flow autoregulation: dynamics and contributions. The American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. 2007; 292: R1–R17.

[68] Seeliger E, Wronski T, Ladwig M, Dobrowolski L, Vogel T, Godes M, et al. The renin-angiotensin system and the third mechanism of renal blood flow autoregulation. American Journal of Physiology-Renal Physiology. 2009; 296: F1334–F1345.

[69] Kopitkó C, Medve L, Gondos T, Soliman KMM, Fülöp T. Mediators of regional kidney perfusion during surgical pneumo-peritoneum creation and the risk of acute kidney injury-a review of basic physiology. Journal of Clinical Medicine. 2022; 11: 2728.

[70] Sorensen CM, Leyssac PP, Salomonsson M, Skott O, Holstein-Rathlou NH. ANG II-induced downregulation of RBF after a prolonged reduction of renal perfusion pressure is due to pre- and postglomerular constriction. The American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. 2004; 286: R865–R873.

[71] Cupples WA. Angiotensin II conditions the slow component of autoregulation of renal blood flow. American Physiological Society Journal. 1993; 264: F515–F522.

[72] Holm L, Morsing P, Casellas D, Persson AE. Resetting of the pressure range for blood flow autoregulation in the rat kidney. Acta Physiologica Scandinavica. 1990; 138: 395–401.

[73] Naguib RE, Contant C, Cupples WA. Atrial natriuretic factor, angiotensin II, and the slow component of renal autoregulation. Canadian Journal of Physiology and Pharmacology. 1994; 72: 1132–1137.

[74] Sorensen CM, Leyssac PP, Skott O, Holstein-Rathlou NH. Role of the renin-angiotensin system in regulation and autoregulation of renal blood flow. The American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. 2000; 279: R1017–R1024.

[75] Abe Y, Kishimoto T, Yamamoto K. Effect of angiotensin II antagonist infusion on autoregulation of renal blood flow. American Physiological Society Journal. 1976; 231: 1267–1271.

[76] Anderson RJ, Taher MS, Cronin RE, McDonald KM, Schrier RW. Effect of beta-adrenergic blockade and inhibitors of angiotensin II and prostaglandins on renal autoregulation. American Physiological Society Journal. 1975; 229: 731–736.

[77] Arendshorst WJ, Finn WF. Renal hemodynamics in the rat before and during inhibition of angiotensin II. American Physiological Society Journal. 1977; 233: F290–F297.

[78] Hall JE, Coleman TG, Guyton AC, Balfe JW, Salgado HC. Intrarenal role of angiotensin II and [des-Asp1]angiotensin II. American Physiological Society Journal. 1979; 236: F252–F259.

[79] Persson P, Ehmke H, Kirchheim H. Influence of the renin-angiotensin system on the autoregulation of renal blood flow and glomerular filtration rate in conscious dogs. Acta Physiologica Scandinavica. 1988; 134: 1–7.

[80] Hellebrekers LJ, Liard JF, Laborde AL, Greene AS, Cowley AW Jr. Regional autoregulatory responses during infusion of vasoconstrictor agents in conscious dogs. American Physiological Society Journal. 1990; 259: H1270–H1277.

[81] Kiil F, Kjekshus J, Löyning E. Renal autoregulation during infusion of noradrenaline, angiotensin and acetylcholine. Acta Physiologica Scandinavica. 1969; 76: 10–23.

[82] Losiggio R, Baiardo Redaelli M, Pruna A, Landoni G, Bellomo R. The renal effects of amino acids infusion. Signa Vitae. 2024; 20: 1–4.

[83] O’Connor WJ, Summerill RA. The effect of a meal of meat on glomerular filtration rate in dogs at normal urine flows. The Journal of Physiology. 1976; 256: 81–91.

[84] Lee KE, Summerill RA. Amino nitrogen metabolism following administration of individual amino acids or meat in conscious dogs. Quarterly Journal of Experimental Physiology. 1982; 67: 449–458.

[85] Sørensen SS, Lauridsen IN, Thomsen K, Pedersen EB. Effect of two regimens of intravenous amino acid infusion on renal haemodynamics, renal tubular function and sodium and water homeostatic hormones in healthy humans. Nephrology Dialysis Transplantation. 1991; 6: 410–419.

[86] Landoni G, Monaco F, Ti LK, Baiardo Redaelli M, Bradic N, Comis M, et al. A randomized trial of intravenous amino acids for kidney protection. The New England Journal of Medicine. 2024; 391: 687–698.

[87] Pruna A, Losiggio R, Landoni G, Kotani Y, Redaelli MB, Veneziano M, et al.; for Protection Study group. Amino acid infusion for perioperative functional renal protection: a meta-analysis. Journal of Cardiothoracic and Vascular Anesthesia. 2024; 38: 3076–3085.

[88] Calice-Silva V, Bensenor IM, Titan SM, Cavalcante MRN, Lotufo PA. Association between branched-chain amino acids and renal function in the ELSA-Brasil study. Clinical Nutrition. 2024; 43: 1051–1056.

[89] Oe Y, Vallon V. CRRT 2023 Meeting: targeting amino acid transport to improve acute kidney injury outcome. Nephron. 2023; 147: 774–777.

[90] De Backer D, Hajjar L, Monnet X. Vasoconstriction in septic shock. Intensive Care Medicine. 2024; 50: 459–462.

[91] Petrun AM, Zdravkovic M, Berger R, Sraka D, Mekis D. Perioperative right ventricular dysfunction in adult patients undergoing non-complex cardiac surgery: diagnosis and management. Signa Vitae. 2023; 19: 11–22.

[92] D’Amico F, Landoni G. Protective hemodynamics: a novel strategy to manage blood pressure. Current Opinion in Critical Care. 2024; 30: 629–636.

[93] Guinot PG, Martin A, Berthoud V, Voizeux P, Bartamian L, Santangelo E, et al. Vasopressor-sparing strategies in patients with shock: a scoping-review and an evidence-based strategy proposition. Journal of Clinical Medicine. 2021; 10: 3164.

[94] Damiani E, Carsetti A, Casarotta E, Domizi R, Scorcella C, Donati A, et al. Microcirculation-guided resuscitation in sepsis: the next frontier? Frontiers in Medicine. 2023; 10: 1212321.